The Challenge

Global plastic consumption is accelerating at a pace the planet cannot absorb. Over 400 million tonnes of plastic are produced annually - half of it single use - equivalent in weight to 800 Burj Khalifa towers (UN, 2025). The plastic lifecycle, from production to disposal, accounts for roughly 4% of global greenhouse gas (GHG) emissions (UNFCCC, 2024). In the EU alone, plastic production generates 13.4 million tonnes of CO₂ yearly, making up 20% of the chemicals sector's total emissions (EEA, 2024).

The waste picture is equally stark. Every day, the equivalent of 2,000 garbage trucks' worth of plastic is discarded into oceans, rivers, and lakes (UNEP, n.d.). Eighty-five percent of marine litter is plastic, driving toxic leaching and habitat degradation across ecosystems (EEA, 2023). The consequences extend beyond the environment - chemical exposure poses human health risks, disrupted fisheries threaten food security, and coastal communities face growing economic fragility.

These pressures are set to intensify. Global annual plastic production is projected to double by 2050 (EEA, 2024), yet global recycling rates remain stuck at just 9%, with incineration accounting for a further 12% (Houssini et al, 2025; EEA, 2024). The scale of the problem demands solutions that go beyond recycling alone - rethinking the materials themselves and the processes used to make them.

The Circular Solution

Mesh Bioplastics, a participant of the 2025 CIRCULÉIRE Venture Accelerator, was founded to address the challenge that the materials used in demanding healthcare and industrial applications needed to meet strict performance requirements while also supporting sustainability and circularity.

The company was co-founded by Shane Hannan, who brings over 15 years of experience across plastics manufacturing and regulated life sciences; Tony Hannan, with 30 years in manufacturing and operational scale-up; Dr. Annie Ibrahim, a specialist in artificial intelligence, data science, and scalable SaaS systems and Reinier Kobus, with 25 years in financial strategy and capital structuring for global conglomerates. Between them, the founding team spans the full range of problems Mesh is built to solve - materials science, manufacturing process control, and the digital intelligence to connect them.

That combination of expertise is reflected in the company's two connected offerings. On the materials side, Mesh develops bioplastics for healthcare, pharmaceuticals, and manufacturing - sectors where performance cannot be compromised. Bioplastics are materials that are bio-based, biodegradable, or both - made wholly or partly from renewable biological sources such as corn, sugarcane, or cellulose, rather than from fossil fuels (European Bioplastics, n.d.). Mesh's biopolymer-based products are designed to match the performance of conventional petroleum-based plastics while significantly reducing environmental harm.

On the manufacturing side, Mesh has developed VariControl - a proprietary AI platform that integrates directly with existing factory-floor equipment including injection moulding, extrusion, and thermoforming machines. Using proactive digital twin technology, VariControl builds a live model of each manufacturing process, continuously monitoring for drift and guiding corrective action before issues reach the production line - improving consistency, reducing waste, and supporting faster learning during manufacturing runs. The platform generates structured, audit-friendly process data designed to support validation-ready production in regulated environments such as healthcare.

VariControl is material-agnostic, operating equally with virgin polymers, recycled polymers, bioplastics, and recycled bioplastic blends. Its ability to learn and model material behaviour also makes it a powerful tool for bringing novel materials online - including emerging bio-based feedstocks derived from aquatic, agricultural, and waste sources - stabilising molecular drift as new materials are introduced and enabling manufacturers to increase recycled or bio-based content progressively, without sacrificing quality or throughput, and without requiring hardware modifications.

Together, these two offerings address the plastic problem from both ends: replacing harmful materials at source and making the production of sustainable alternatives as efficient and commercially viable as possible.

Climate Impact

Under optimised conditions, bioplastics produced from lignocellulosic waste biomass (plant-based agricultural and forestry residues such as wheat straw, corn husks, and sawdust) can achieve carbon-negative lifecycle emissions, while food waste-derived bioplastics generate just 4.8 kg CO₂ eq. per kilogram produced - far below conventional fossil plastic benchmarks (de Mello et al., 2025).

VariControl delivers additional gains at the production stage. The company’s own pilot trials in plastics manufacturing have reported measurable sustainability improvements through real-time optimisation and waste minimisation:

• 20–25% average reduction in material waste through predictive fault detection and closed-loop process control.

  
  

• Up to 15% decrease in energy consumption production run due to dynamic cycle-time optimisation.

  
  

• Support for up to 50% recycled or bioplastic content without sacrificing quality or throughput, slashing virgin polymer reliance.

  
  

• 25–35% drop in process-related CO₂ emissions versus conventional virgin-material production.

  
  

Beyond the environmental gains, VariControl reduces raw material costs and waste disposal fees - improving profit margins and making the transition to circular plastics production a commercially attractive proposition for manufacturers, not just a compliance exercise.

Replicability

The global medical plastics market - the primary target for Mesh's biopolymer-based devices - was valued at USD $61.35 billion in 2025 and is projected to reach USD $99.25 billion by 2033, growing at a CAGR of 6.0% (Grand View Research, 2025).

At the same time, the broader bioplastics sector is scaling rapidly. According to the European Bioplastics Association, global biobased plastics production capacity is forecast to double from 2.31 million tonnes in 2025 to approximately 4.69 million tonnes by 2030, driven by regulatory pressure, rising demand across packaging, automotive, and healthcare, and the emergence of more advanced applications (European Bioplastics, 2025).

EU regulation is tightening the conditions under which conventional plastics can be produced and placed on the market. The Packaging and Packaging Waste Regulation and the Corporate Sustainability Reporting Directive (CSRD) are together mandating reductions in virgin material use and greater transparency around environmental performance - creating both pressure and opportunity for solutions like those Mesh Bioplastics offers.

A number of organisations are developing comparable solutions in the bioplastics and circular plastics space:

• ReBioCycle is an EU-funded initiative scaling sorting and recycling infrastructure for bio-based plastics, improving recycled content and measuring environmental performance against fossil benchmarks.

  
  

• Sulapac (Finland) develops wood-based biocomposite materials for cosmetics packaging, achieving full biodegradability without compromising on design or performance.

  
  

• Corbion (Netherlands) produces lactic acid-based biopolymers used in medical applications including wound care, surgical sutures, and drug delivery systems, applying fermentation-based production processes and rigorous regulatory compliance to support sustainable healthcare materials.

  
  

• NatureWorks (USA) is one of the world's leading producers of Ingeo biopolymers, derived from renewable resources, with applications spanning packaging, medical devices, and industrial uses - demonstrating the commercial scalability of bio-based alternatives to conventional plastics.